Since ER, PgR and HER2 expression levels can change in metastatic lesions in patients with breast cancer [28] and lead to drug resistance, a biopsy of suspected metastatic lesions is recommended in these patients for the analysis of ER, PgR and HER2 expression [29, 30]. Here, ERBB2 is linked to breast cancer.